Direna Alonso-Curbelo

Direna Alonso-Curbelo

Auto-generated profile, based on publicly available information

Direna Alonso-Curbelo

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
NTNilgun Tasdemir
Nilgun Tasdemir
ABAna Banito
Ana Banito
JRJae-Seok Roe
Jae-Seok Roe
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
MCMatthew Camiolo
Matthew Camiolo
SLScott W. Lowe
Scott W. Lowe
Oncogene-induced senescence is a potent barrier to tumorigenesis that limits cellular expansion following certain oncogenic events. Senescent cells display a repressive chromatin configuration thought to stably silence proliferation-promoting genes while simultaneously activating an unusual form of immune surveillance involving a secretory program referred to as the senescence-associated secretory phenotype (SASP). Here, we demonstrate that senescence also involves a global remodeling of the enhancer landscape with recruitment of the chromatin reader BRD4 to newly activated super-enhancers adjacent to key SASP genes. Transcriptional profiling and functional studies indicate that BRD4 is required for the SASP and downstream paracrine signaling. Consequently, BRD4 inhibition disrupts immune cell–mediated targeting and elimination of premalignant senescent cells in vitro and in vivo. Our results identify a critical role for BRD4-bound super-enhancers in senescence immune surveillance and in the proper execution of a tumor-suppressive program. Significance: This study reveals how cells undergoing oncogene-induced senescence acquire a distinctive enhancer landscape that includes formation of super-enhancers adjacent to immune-modulatory genes required for paracrine immune activation. This process links BRD4 and super-enhancers to a tumor-suppressive immune surveillance program that can be disrupted by small molecule inhibitors of the bromo and extra terminal domain family of proteins. Cancer Discov; 6(6); 612–29. ©2016 AACR. See related commentary by Vizioli and Adams, p. 576. This article is highlighted in the In This Issue feature, p. 561

27 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HCHsuan-An Chen
Hsuan-An Chen
YHYu-Jui Ho
Yu-Jui Ho
RMRiccardo Mezzadra
Riccardo Mezzadra
JAJose M. Adrover
Jose M. Adrover
RSRyan Smolkin
Ryan Smolkin
SLScott W. Lowe
Scott W. Lowe
Cellular senescence involves a stable cell-cycle arrest coupled to a secretory program that, in some instances, stimulates the immune clearance of senescent cells. Using an immune-competent liver cancer model in which senescence triggers CD8 T cell–mediated tumor rejection, we show that senescence also remodels the cell-surface proteome to alter how tumor cells sense environmental factors, as exemplified by type II interferon (IFNγ). Compared with proliferating cells, senescent cells upregulate the IFNγ receptor, become hypersensitized to microenvironmental IFNγ, and more robustly induce the antigen-presenting machinery—effects also recapitulated in human tumor cells undergoing therapy-induced senescence. Disruption of IFNγ sensing in senescent cells blunts their immune-mediated clearance without disabling the senescence state or its characteristic secretory program. Our results demonstrate that senescent cells have an enhanced ability to both send and receive environmental signals and imply that each process is required for their effective immune surveillance. Significance: Our work uncovers an interplay between tissue remodeling and tissue-sensing programs that can be engaged by senescence in advanced cancers to render tumor cells more visible to the adaptive immune system. This new facet of senescence establishes reciprocal heterotypic signaling interactions that can be induced therapeutically to enhance antitumor immunity. See the interview with Direna Alonso-Curbelo, PhD, recipient of the inaugural Cancer Discovery Early Career Award: https://vimeo.com/992987447 See related article by Marin et al., p. 410. This article is highlighted in the In This Issue feature, p. 247

12 May 2023 in Science
Verified
Journal Article
Open access
CBCassandra Burdziak
Cassandra Burdziak
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
TWThomas Walle
Thomas Walle
JRJosé Reyes
José Reyes
FBFrancisco M. Barriga
Francisco M. Barriga
DPDana Pe’eR
Dana Pe’eR
The response to tumor-initiating inflammatory and genetic insults can vary among morphologically indistinguishable cells, suggesting as yet uncharacterized roles for epigenetic plasticity during early neoplasia. To investigate the origins and impact of such plasticity, we performed single-cell analyses on normal, inflamed, premalignant, and malignant tissues in autochthonous models of pancreatic cancer. We reproducibly identified heterogeneous cell states that are primed for diverse, late-emerging neoplastic fates and linked these to chromatin remodeling at cell-cell communication loci. Using an inference approach, we revealed signaling gene modules and tissue-level cross-talk, including a neoplasia-driving feedback loop between discrete epithelial and immune cell populations that was functionally validated in mice. Our results uncover a neoplasia-specific tissue-remodeling program that may be exploited for pancreatic cancer interception.

1 August 2009 in Cancer Cell
Verified
Journal Article
Closed access
DTDamià Tormo
Damià Tormo
ACAgnieszka Chęcińska
Agnieszka Chęcińska
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
EPEva Pérez-Guijarro
Eva Pérez-Guijarro
ECEstela Cañón
Estela Cañón
MSMaría S. Soengas
María S. Soengas

28 June 2017 in Nature
Verified
Journal Article
Open access
PDF file
DODavid Olmeda
David Olmeda
DCDaniela Cerezo-Wallis
Daniela Cerezo-Wallis
ERErica Riveiro-Falkenbach
Erica Riveiro-Falkenbach
PPPaula C. Pennacchi
Paula C. Pennacchi
MCMarta Contreras-Alcalde
Marta Contreras-Alcalde
MSMaría S. Soengas
María S. Soengas
Genetically engineered ‘lymphoreporter’ mouse strains are used to track melanoma dissemination in vivo, identifying midkine as a tumour-secreted factor that acts at a distance, preparing pre-metastatic niches and serving as an indicator of poor prognosis in patients. Lymph nodes are a common metastatic site of many tumour types, including melanomas. The contribution of lymphangiogenesis to metastatic progression is not well defined, as removing the sentinel lymph node does not always improve the survival chances of melanoma patients. Here the authors develop a 'lymphoreporter' mouse model that allows them to track lymphatic vessels with a VEGFR3 reporter, and use it to visualize metastatic routes during relapse. In addition, the authors identify a mediator of lymphangiogenesis, MIDKINE, that contributes to metastasis and indicates a poor prognosis for patients with melanoma. The authors suggest that VEGFR3 reporters could be useful in the search for further drivers and inhibitors of metastasis. Cutaneous melanoma is a type of cancer with an inherent potential for lymph node colonization, which is generally preceded by neolymphangiogenesis1,2,3. However, sentinel lymph node removal does not necessarily extend the overall survival of patients with melanoma4,5. Moreover, lymphatic vessels collapse and become dysfunctional as melanomas progress6,7. Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis. Soluble and vesicle-associated proteins secreted by tumours and/or their stroma have been proposed to condition pre-metastatic sites in patients with melanoma8,9,10,11,12,13,14. Still, the identities and prognostic value of lymphangiogenic mediators remain unclear2,14. Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types) is limited by the paucity of mouse models for live imaging of distal pre-metastatic niches15. Injectable lymphatic tracers have been developed7, but their limited diffusion precludes whole-body imaging at visceral sites16. Vascular endothelial growth factor receptor 3 (VEGFR3) is an attractive ‘lymphoreporter’17 because its expression is strongly downregulated in normal adult lymphatic endothelial cells, but is activated in pathological situations such as inflammation and cancer17,18. Here, we exploit this inducibility of VEGFR3 to engineer mouse melanoma models for whole-body imaging of metastasis generated by human cells, clinical biopsies or endogenously deregulated oncogenic pathways. This strategy revealed early induction of distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions. Analyses of the melanoma secretome and validation in clinical specimens showed that the heparin-binding factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis. This role of midkine was linked to a paracrine activation of the mTOR pathway in lymphatic endothelial cells. These data support the use of VEGFR3 reporter mice as a ‘MetAlert’ discovery platform for drivers and inhibitors of metastasis.

25 April 2024 in Cancer Cell
Verified
Journal Article
Closed access
CBCamille Blériot
Camille Blériot
GDGarett Dunsmore
Garett Dunsmore
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
FGFlorent Ginhoux
Florent Ginhoux